Abstract Mutations in the breast cancer susceptibility genes BRCA1, BRCA2, and CHEK2 are known risk factors for female breast cancer. Mutations in BRCA1 and BRCA2 also are associated with male breast cancer (MBC). Similarly, it had been suggested in the original CHEK2 identification report that the CHEK2 1100delC mutation confers an increased risk for MBC. Here, we have evaluated the risk of CHEK2 1100delC for MBC by genotyping CHEK2 1100delC in 23 familial and 71 unselected Dutch MBC cases. None of the 23 familial MBC cases carried the CHEK2 1100delC mutation. In contrast, CHEK2 1100delC was present in 3 of the 71 (4.2%) unselected MBC cases, which was significantly more prevalent than the 1.1% Dutch population frequency assessed in 1,692 individuals (P = 0.05, OR = 4.1, 95% CI 1.2-14.3). Our data suggest that, in the Netherlands, CHEK2 1100delC is associated with an increased risk for MBC.
Introduction
Male breast cancer (MBC) is a rare disease that accounts for less than 1% of all breast cancers. Major risk factors for MBC are Klinefelter syndrome, disorders associated with high estrogen levels, testicular disorders, and a family history of breast cancer. Germ line mutations in the breast cancer susceptibility genes BRCA2 and BRCA1 account for approximately 4-14% of familial MBC cases, with higher frequencies found in BRCA2 founder populations [1] . Apart from BRCA2 and BRCA1 mutations, mutations in the androgen receptor, the CYP17 and the PTEN genes have also been implicated in MBC [1] [2] [3] . Yet, it is still unclear what the underlying predisposition in the majority of MBC cases is.
In 2002, we and others identified the CHEK2 1100delC mutation as a breast cancer susceptibility allele [4, 5] . We estimated that female CHEK2 1100delC carriers had a twofold increased breast cancer risk compared with noncarriers, classifying the mutation as a moderate-risk breast cancer susceptibility allele [6] . In addition to a female breast cancer risk, 4 of 33 (12%) index cases of families with at least one MBC case were CHEK2 1100delC positive suggesting that the mutation also might confer a risk for MBC [4] . Thus far, the prevalence of CHEK2 1100delC in MBC has been evaluated in 12 additional studies [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] . Yet, only 3 of 627 genotyped samples carried the CHEK2 1100delC mutation, raising doubts on the association of CHEK2 1100delC with MBC. Evaluation of CHEK2 1100delC in MBC is however severely hampered by the moderate cancer risks associated with CHEK2 1100delC, the large differences in CHEK2 1100delC population frequencies and the rarity of the MBC phenotype.
In the Netherlands, the relatively high CHEK2 1100delC population frequency of 1.1% previously had allowed the identification of CHEK2 1100delC as a breast cancer allele and a colorectal cancer allele [4, 19, 20] . Here, we have exploited our unique opportunity to assess CHEK2 1100delC-associated cancer risks by screening CHEK2 1100delC in 94 Dutch MBC cases.
Materials and methods

Male breast cancer cases and controls
The evaluated MBC cohort consisted of 23 familial and 71 unselected MBC cases, together including all available MBC cases registered at Erasmus MC. All familial breast cancer cases were ascertained through the Rotterdam Family Cancer Clinic at Erasmus MC (Table 1) . A family history of MBC was defined by the presence of at least two breast cancer cases in first-or second-degree relatives of whom at least one was a man (21 families) or by the presence of at least one MBC case who had two or more first-degree relatives diagnosed with cancer types other than breast carcinoma (2 families). Screening of all 23 MBC families had identified BRCA2 and BRCA1 germ line mutations in five and three families, respectively. The CHEK2 1100delC mutation was tested in blood-derived DNA of 14 MBC cases and in 17 first-degree relatives of 9 MBC cases of whom no DNA was available (Table 1) . Unselected MBC cases included all available MBC cases from the Erasmus MC Pathology archive (16 paraffin-embedded tumors), the Rotterdam Family Cancer Clinic (3 blood-derived DNA samples), and the Rotterdam Medical Oncology Tumor Bank (52 fresh-frozen tumors). None of the unselected MBC cases had been screened for BRCA1 or BRCA2 mutations. Of note, 25 fresh-frozen MBC tumors had also been part of a previous study that had evaluated the clinical relevance of steroid hormones and factors involved in the urokinase system among male and female breast cancers [21] . The Medical Ethical Review Board at Erasmus MC has approved the study, which was carried out according to the Code of Conduct of the Federation of Medical Scientific Societies in the Netherlands (http://www.fmwv.nl/).
Population controls were previously reported and included a hospital-based cohort of 967 spouses of heterozygous cystic fibrosis mutation carriers registered by the department of Clinical Genetics at Erasmus MC, a population-based cohort of 460 persons without cancer after age 55 years from the Erasmus Rotterdam Health and the Elderly Study (ERGO) and a cohort of 265 randomly selected blood donors [6, 22] .
CHEK2 1100delC genotyping
CHEK2 1100delC genotyping was performed on DNA by allele-specific oligonucleotide hybridization, with confirmation of mutant cases by long-range PCR and sequencing of an independent template, as described [4] .
Statistics
The difference between CHEK2 1100delC frequency in cancer cases and controls among CHEK2 1100delC carriers versus non-carriers was tested by using Fisher's Exact Test. Odds ratios (OR) and corresponding 95% confidence intervals (95% CI) were calculated using Woolf's method. All statistical analyses were performed with STATA statistical package, release 10 (STATA Corp, College Station, TX).
Results and discussion
Genotyping of CHEK2 1100delC identified 3 of 94 MBC cases (3.2%) as heterozygous carriers of the CHEK2 1100delC mutation (Table 2 ). All three CHEK2 1100delC cases were identified among the 71 unselected MBC cases (4.2%, Table 2 ), which was significantly more prevalent compared with the 1.1% Dutch population frequency (P = 0.05, OR = 4.1, 95% CI 1.2-14.3). Our results thus suggest that CHEK2 1100delC is associated with an increased risk for MBC in the Dutch population.
Age at diagnosis and cytosolic estrogen receptor (ER) and progesterone receptor (PgR) levels were available for 50 unselected MBC cases including all three CHEK2 1100delC All three CHEK2 1100delC cases were ER positive as were 41 of 47 (87%) CHEK2 1100delC negative cases. Similar, two of the three CHEK2 1100delC MBC cases (67%) were PgR positive compared to 37 of 47 (78%) CHEK2 1100delC negative cases. Clinical follow-up including tumor stage, lymph node involvement, local and/or distant metastasis data were available for two CHEK2 1100delC and 33 CHEK2 1100delC negative unselected MBC cases. Overall, the median follow-up time of MBC cases still alive was 47 months (range 2-165 months). The first CHEK2 1100delC case was diagnosed with a lymph node-negative T1 breast tumor and the second case had a lymph node-positive T4 breast tumor. Both cases died of bone metastasis, 24 and 36 months after their diagnosis, respectively. In contrast, distant metastasis at diagnosis and during follow-up was reported in 12 of 33 (36%) CHEK2 1100delC negative MBC cases and only two of these had a sole relapse to the bone. In agreement with previous reports on bone metastatic disease and ER status, all four MBC cases diagnosed with bone metastasis were ER positive, affirming the strong association between relapse to bone and positive ER status [23, 24] . In the initial CHEK2 1100delC identification report, 4 unrelated CHEK2 1100delC cases had been identified among 33 (12%) high-risk BRCA1/BRCA2 negative MBC families, suggesting an estimated 10-fold increased MBC risk for CHEK2 1100delC MBC carriers [4] . Yet, here we did not identify CHEK2 1100delC among the 23 familial MBC cases analyzed. The analyzed familial MBC cohort included eight confirmed BRCA1/BRCA2 positive MBC cases (Table 1) . These cases were a priori unlikely to carry CHEK2 1100delC as the CHEK2 1100delC mutation is quite uncommon among BRCA1/BRCA2 mutation carriers [4, 6] . Additionally, four BRCA1/BRCA2 negative families had been included for which the MBC case was not available for CHEK2 1100delC genotyping ( Table 1) . As a whole, we thus had 11 BRCA1/ BRCA2 negative familial MBC cases available for CHEK2 1100delC analysis, a too low number to establish a possible correlation between CHEK2 1100delC and familial BRCA1/ BRCA2 negative breast cancer.
In addition to our previous 4 of 33 MBC cases [4] , thus far, only three CHEK2 1100delC cases have been identified worldwide among the additional 627 MBC cases genotyped (Table 2) [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] . In contrast to the initial CHEK2 1100delC identification report [4] and our current report, this low frequency of 0.5% (3 of 627 MBC cases) had suggested that CHEK2 1100delC is not a risk allele for MBC. However, most of the reported studies had low CHEK2 1100delC population frequencies and also had used small MBC cohorts [4, [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] , resulting in a lack of statistical power to detect CHEK2 1100delC-associated cancer risks. Interestingly, the Finnish CHEK2 1100delC MBC study had comparable power to our study, but failed to identify a CHEK2 1100delC related MBC risk [13, 18] . Similarly, we previously had identified CHEK2 1100delC as a risk allele for Dutch colorectal cancer cases whereas no such risk could be detected for Finnish colorectal cancer cases [20, 25] . These observations might suggest the presence of additional susceptibility alleles in the Dutch population that are absent 
